Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.40 |
| ▸ | RELA | Q04206 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15656023 | 0.89 | GSK3A (0.46) | GSK3AGSK3BADORA1ADORA3RAB9A | |
| SCHEMBL15655811 | 0.78 | ADORA3 (0.47) | GSK3AGSK3BADORA2BADORA1ADORA3 | |
| SCHEMBL15656718 | 0.77 | ADORA2A (0.47) | ADORA2BADORA1ADORA2AMAPTMAP2K4 | |
| SCHEMBL15657196 | 0.76 | GSK3A (0.42) | GSK3AGSK3BADORA3RAB9ASMN1; SMN2 | |
| SCHEMBL15656110 | 0.75 | GSK3A (0.39) | GSK3AGSK3BADORA3RAB9ASMN1; SMN2 | |
| SCHEMBL13737429 | 0.70 | KMT2A (0.44) | ADORA3MAPTSMN1; SMN2LMNANPSR1 | |
| SCHEMBL2868379 | 0.68 | TTK (0.47) | GSK3AGSK3BADORA2BADORA1ADORA3 | |
| SCHEMBL2863255 | 0.68 | TTK (0.47) | GSK3AGSK3BADORA2BADORA1ADORA3 | |
| SCHEMBL2860783 | 0.68 | MAP2K4 (0.52) | GSK3AGSK3BADORA2BADORA1ADORA3 | |
| SCHEMBL8889925 | 0.68 | MAP2K4 (0.45) | ADORA2BADORA1ADORA3ADORA2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2911671-B1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE INC (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2911671-B1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE INC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-9783545-B2 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | USHER III INITIATIVE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783545-B2 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | USHER III INITIATIVE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783545-B2 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | USHER III INITIATIVE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160272647-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | BIOFOCUS DPI LTD. (GB) | 2016-09-22 | — | — | US | disclosed |
| US-20160272647-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | BIOFOCUS DPI LTD. (GB) | 2016-09-22 | — | — | US | disclosed |
| US-20160272647-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | BIOFOCUS DPI LTD. (GB) | 2016-09-22 | — | — | US | disclosed |
| US-9371332-B2 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher syndrome | USHER III INITIATIVE, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371332-B2 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher syndrome | USHER III INITIATIVE, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20140121205-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140121197-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE, INC. | 2014-05-01 | — | — | US | disclosed |
| US-20140121205-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140121205-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140121197-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE, INC. | 2014-05-01 | — | — | US | disclosed |
| US-20140121197-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE, INC. | 2014-05-01 | — | — | US | disclosed |
| WO-2014066835-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE, INC. (US) | 2014-05-01 | — | — | WO | disclosed |
| WO-2014066836-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE, INC. (US) | 2014-05-01 | — | — | WO | disclosed |
| WO-2014066836-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE, INC. (US) | 2014-05-01 | — | — | WO | disclosed |
| WO-2014066835-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE, INC. (US) | 2014-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272647-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | ALDH1A2, ALDH1A3, NR2E3 | GSK3A 3852/4885GSK3B 3628/4885ADORA2B 1639/4885 |
| US-20140121205-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | ALDH1A2, ALDH1A3, PSEN2 | GSK3A 3723/4885GSK3B 3495/4885ADORA2B 1708/4885 |
| US-20140121197-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | ALDH1A2, ALDH1A3, NR2E3 | GSK3A 3852/4885GSK3B 3628/4885ADORA2B 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.